correspondence

concern was exclusively over the quality of the scientific data and conclusions, which would have been the same whatever the motivation of the criticism.

Bad science can only undermine our understanding of nature, and the making of constructive public policy. The statement that "commercially vested interests" (that is, ties to Syngenta/ Novartis) are "central to" criticisms of the data in ref. 4 is as useless in addressing the scientific issues as would be an accusation that these data were tainted by a grudge between Chapela and his former employer (the same company). Although our connections to industry are irrelevant to the scientific issues, and hence do not warrant disclosure, we feel compelled to dispel the mischaracterization of Worthy et al.. One of us (M. M.) had TMRI funding for only one-sixth of his study at UC Berkeley, and the other's (J. F.) alleged link to TMRI relies entirely on someone else's former Berkeley association. Both of us currently have research funding exclusively from the public sector.

We are not unlike many scientists in that we have shared research and funding with industry at some point. In stating that we have "compromised positions", Worthy *et al.* wrongly imply that private-sector funding strips us of integrity and legitimacy in the arena of scientific discourse. Far from promoting "scientific freedom and balance",

this presumption tars any scientist who can be suggested to have worked with the private sector. The only threat to academic freedom that seems to have materialized from the Berkeley/TMRI collaboration is this attitude towards scientists who might have industry links.

Matthew Metz*

Johannes Fütterer†

*Department of Microbiology, University of Washington, Seattle, Washington 98195, USA †Institute of Plant Sciences, ETH, CH-8092 Zürich, Switzerland

Kaplinsky replies — I, on behalf of the authors of our Brief Communication², state unequivocally that funding from TMRI has absolutely nothing to do with our criticisms. Worthy and co-authors are incorrect. Two of my co-authors of ref. 2 (Hake and Hay) do not receive any industry funding. Funding information for the Freeling lab (Braun, Freeling, Lisch and N. K.) is transparent and public (see http://plantbio.berkeley.edu/~freeling/lab web/fund.html); less than a quarter of it is from industry.

As Worthy et al. state, Chapela and Quist are "leading critics" of the TMRI agreement. Chapela is a board member of PANNA (http://www.panna.org/panna/about/board.html#ihc), an advocacy group opposing genetically modified organisms (GMOs). It is a double standard

to accuse us, but not Quist and Chapela, of a conflict of interest.

Our letter was a critique of poorly conducted and interpreted science and was not pro- or anti-GMO or industry. We simply corrected what we think is bad science. Even if we were in the pockets of industry, Quist and Chapela's published results⁴ would still be artefactual.

Nick Kaplinsky

Department of Plant and Microbial Biology, University of California, Berkeley, California 94720 USA

- 1. Metz, M. & Fütterer, J. Nature 416, 600-601 (2002).
- 2. Kaplinsky, N. et al. Nature 416, 601 (2002).
- 3. Quist, D. & Chapela, I. H. Nature 416, 602 (2002).
- 4. Quist, D. & Chapela, I. H. Nature 414, 541-543 (2001).

Nature comments:

It is highly unusual for *Nature* to publish a paper whose principal conclusion is shown to be not necessarily false but unsustainable on the basis of the reported evidence. The paper was not formally retracted by its authors or by *Nature*. In the circumstances, *Nature* considered it appropriate for the record to make clear to readers its revised view of its original decision to publish.

The independence of our editorial decision-making from partisan anti- or pro-technology agendas and from commercial interests is paramount in our role as a journal. Editor, *Nature*

Impact-factor rewards affect Spanish research

Sir — In Spain, as in Finland¹, publication of research reports in journals with a high impact factor has since 1989 officially been part of the national system for evaluating researchers' productivity. But unlike the Finnish system, the Spanish system rewards individuals rather than departments or institutions.

As stated in the Spanish parliamentary record^{2,3}, a bonus is awarded only for "those articles of scientific worth in journals of recognized prestige in the field. As a quality indicator, the relevance of the medium of dissemination in which each article was published shall be considered. In those disciplines for which international systems of quality of publications exist, reliance on these systems shall be obligatory."

What exactly are these "systems of quality of publication"? In mathematics and physics, chemistry, cell and molecular biology, medicine, natural science, engineering and architecture, economics and social science, the law specifies that "preference shall be given to those contributions consisting of articles in journals of

recognized prestige, which shall be accepted to mean those that occupy relevant positions in the lists for science fields in the Subject Category Listings of the Journal Citation Reports of the Science Citation Index (Institute for Scientific Information [ISI], Philadelphia, PA, USA)" (ref. 4). For the first four fields, the National Commission for the Evaluation of Research Activity (CNEAI) recommends that articles should be published in journals that occupy a relevant position in the pertinent ranking, which is understood to mean the upper third of the listing ranked by impact factor. There may, however, be some flexibility under special circumstances at the discretion of the experts. The aim of this reward system is to improve the quality of Spanish science and its visibility in journals.

The consequences of this law have been first, a change in Spanish scientists' publication habits; second, an increase in the number of Spanish source items in the ISI databases^{5,6}; and third, a levelling off of source items in Spanish bibliographic databases⁷. Spanish scientific productivity has doubled: more than twice as many papers were published between 1991 (immediately after the system of publication bonuses was passed into law)

and 1998 compared with the period 1982–1990. The acceleration in national publication output cannot be attributed to increased financial support (research budgets had begun to shrink in real terms by 1991), international collaboration or mobility of researchers, nor can it be attributed to an overall increase in scientific activity⁸.

We thank K. Shashok for translating this Correspondence into English. Evaristo Jiménez-Contreras*, Emilio Delgado López-Cózar*, Rafael Ruiz-Pérez*, Víctor M. Fernández†

*Department of Library and Information Science, School of Library and Information Science, University of Granada, 18071 Granada, Spain †Former director, National Commission for the Evaluation of Research Activity (CNEAI), Department of Biocatalysis, Institute of Catalysis, CSIC, 28049 Madrid, Spain

- 1. Adam, D. Nature 415, 726-729 (2002).
- 2. Boletín Oficial del Estado 28563 (9 September 1989)
- Boletín Oficial del Estado 3566 (6 February 1990); Boletín Oficial del Estado 37030 (3 December 1994).
- 4. Boletín Oficial del Estado 35028 (20 November 1996).
- Garfield, E. www.garfield.library.upenn.edu/papers/ mapsciworld.html.
- 6. Gómez, I., Bordons, M., Camí, J. Science 276, 883–884 (1997).
- 7. Fernández, M. T., Bordons, M., Sancho, R., Gómez, I. *Arbor* **639**, 327–345 (1999).
- Jiménez-Contreras, E., Moya, F., Delgado López-Cózar, E. Research Policy 2002 (in the press).